Search

Your search keyword '"Hao, Yanrong"' showing total 151 results

Search Constraints

Start Over You searched for: Author "Hao, Yanrong" Remove constraint Author: "Hao, Yanrong"
151 results on '"Hao, Yanrong"'

Search Results

1. MCDGLN: Masked Connection-based Dynamic Graph Learning Network for Autism Spectrum Disorder

2. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer

4. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

7. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

9. Associations between COVID-19 related stigma and sleep quality among COVID-19 survivors six months after hospital discharge

18. Altered Brain Dynamics and Their Ability for Major Depression Detection Using EEG Microstates Analysis.

21. Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.

22. Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.

23. Depression, anxiety and post-traumatic growth among COVID-19 survivors six-month after discharge

24. Effective Connectivity Based EEG Revealing the Inhibitory Deficits for Distracting Stimuli in Major Depression Disorders.

25. Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

26. Hospitalization, interpersonal and personal factors of social anxiety among COVID-19 survivors at the six-month follow-up after hospital treatment: the minority stress model

28. Post-traumatic Stress Disorder Symptoms in COVID-19 Survivors 6 Months After Hospital Discharge: An Application of the Conservation of Resource Theory

31. Furmonertinib (AST2818) Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multi-Center, Double-Blind, Randomized Phase 3 Study (FURLONG)

32. Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: cross-sectional survey in five cities in China – CORRIGENDUM

38. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFRmutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

41. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase

42. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFRmutation-positive non-small cell lung cancer

49. Long Noncoding RNAs and Messenger RNAs Expression Profiles Potentially Regulated by ZBTB7A in Nasopharyngeal Carcinoma

Catalog

Books, media, physical & digital resources